Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The IL-17–TH17 pathway is a popular target for the treatment of psoriasis and other autoimmune conditions. Bartlett and Million discuss the key agents in the pipeline, several of which are expected to gain approval in the near future.
Butlen-Ducuing and colleagues analyse ~20 years of data on regulatory applications assesssed by the European Medicines Agency in psychiatry and neurology, with the aim of illuminating challenges that underlie the 'pipeline problem' for drugs for central nervous system disorders.
Checkpoint inhibitors, which stimulate the anticancer activity of T cells, are the most advanced class of cancer immunotherapies. This analysis examines the pipeline of agents in development and their market potential.
This analysis examines new classes of drugs that are in development for dyslipidaemia — in particular PCSK9 inhibitors and CETP inhibitors — and discusses their likely impact on the dyslipidaemia market, which is currently dominated by statins.
Current treatments for cystic fibrosis are largely symptomatic, but the first disease-modifying drug has recently been approved and others are progressing. This article examines the multitude of agents in the clinical pipeline and their potential market impact in the next 5 years.
The developmental pipeline of HIV antiretroviral therapies is large and diverse, spanning a number of different drug classes. This article provides an overview of the agents in development, including combination therapies, and an analysis of the market for current and future HIV treatments.
Thrombotic events are a major complication of cardiovascular disease. Despite the availability of a large range of antithrombotic therapies, demand persists for safe, effective new drugs and antidotes that allow control of their activity. This article investigates the antithrombotic drug pipeline and the changing landscape of the antithrombotics market.
Webster and Mentzer discuss the market landscape for malignant melanoma — a cancer for which treatment options have broadened substantially in recent years, with several new drugs also soon expected to gain approval.
Analysis of the value of new drug approvals over the past two decades, together with spending by industry on research and development (R&D), indicates that the R&D productivity for the industry overall has moved back towards a sustainable level, driven by several companies that are substantially outperforming the average.
Next-generation antibody (NGA) therapeutics incorporate architectural changes that allow for increased efficacy and product differentiation. This analysis provides an overview of the different types of NGAs in development and an outlook of their market potential.
Therapeutic approaches to treat chronic obstructive pulmonary disease (COPD) are varied and recent approvals have diversified treatment options. Here, Mushtaq discusses the current COPD pipeline and provides a market outlook for newly approved and late-stage drugs.
The late-stage pipeline for systemic lupus erythematosus (SLE) and lupus nephritis (LN) contains biologics and small-molecule drugs for a broad range of different targets. Koutsokeras and Healy discuss their likely impact on the future SLE and LN market.
Grabowski and colleagues analyse the European market uptake of biosimilar versions of two major therapeutic biologics — epoetin alfa and filgrastim — and discuss the implications for the future development of the market for biosimilars.
